Akin Begum Gorgulu, Kar Irem, Aydin Omur
Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine.
Immunology and Allergy, Ankara City Hospital.
Asian Pac J Allergy Immunol. 2024 Jan 6. doi: 10.12932/AP-090523-1607.
Allergic rhinitis (AR) is defined as an inflammatory disease of the nose. Nasal corticosteroids (NCS) are one of the most effective drugs used in AR treatment.
One of the most important issues in the treatment of AR is patient adherence to NCS. We aimed to evaluate the adherence and attitude of patients with AR to NCS treatment.
One hundred four patients who were prescribed NCS for AR at any time and who used NCS during the study period were included in the study. Morisky Medical Adherence Scale-8 (MMAS-8) was performed on the patients to determine their treatment adherence.
The scores of the MMAS-8 were below 6 in 55% of the patients, and the adherence of the patients to the NCS treatment was low. The adherence of the patients to NCS treatment was good in only 19% of the patients. As the duration of the disease increased, the adherence of the patients to the treatment decreased (p = 0.001). Patients who benefited from allergen immunotherapy had statistically significantly higher MMAS-8 scores than those who did not (p = 0.015). As expected, drug adherence was statistically significantly lower in patients with drug-related adverse effects (p = 0.01). Sixty percent of the patients had received NCS training, and MMAS-8 scores were significantly higher in those who received training (p = 0.023).
Inadequate drug adherence is a challenging problem in the treatment of AR. Frequent evaluation of patients' drug adherence and drug use techniques in daily practice is important for the follow-up and treatment of the disease.
变应性鼻炎（AR）被定义为一种鼻部炎症性疾病。鼻用糖皮质激素（NCS）是用于AR治疗的最有效药物之一。
AR治疗中最重要的问题之一是患者对NCS的依从性。我们旨在评估AR患者对NCS治疗的依从性和态度。
本研究纳入了104例曾在任何时间被处方使用NCS治疗AR且在研究期间使用了NCS的患者。采用Morisky药物依从性量表-8（MMAS-8）对患者进行评估以确定其治疗依从性。
55%的患者MMAS-8评分低于6分，患者对NCS治疗的依从性较低。仅19%的患者对NCS治疗的依从性良好。随着疾病持续时间的增加，患者对治疗的依从性下降（p = 0.001）。从变应原免疫治疗中获益的患者MMAS-8评分在统计学上显著高于未获益的患者（p = 0.015）。正如预期的那样，有药物相关不良反应的患者药物依从性在统计学上显著更低（p = 0.01）。60%的患者接受了NCS培训，接受培训的患者MMAS-8评分显著更高（p = 0.023）。
药物依从性不足是AR治疗中一个具有挑战性的问题。在日常实践中频繁评估患者的药物依从性和用药技巧对于疾病的随访和治疗很重要。
